NCT06116292 Impact of the Implementation of a Telemedicine Program on Patients Diagnosed with Asthma
| NCT ID | NCT06116292 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital Universitari de Bellvitge |
| Condition | Asthma |
| Study Type | INTERVENTIONAL |
| Enrollment | 108 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 108 participants in total. It began in 2024-01-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Introduction: Asthma is one of the most common chronic respiratory diseases worldwide. Despite the extensive knowledge of the condition and available therapeutic options, severe asthmatic patients have poor disease control in 50% of cases. Objective: To assess the impact of implementing a mobile application (ESTOI) in patients diagnosed with asthma on disease control, treatment adherence, and perceived quality of life. Methodology: A 52-week randomized clinical trial involving asthma patients receiving care at a highly specialized hospital in Spain. A total of 108 patients will be included and divided into two groups. The intervention group will receive more comprehensive monitoring than usual, including access to the ESTOI application. The Asthma Control Test (ACT) questionnaire will be used as the primary assessment variable. Other variables to be studied include the Inhaler Adherence Test (TAI), the number of exacerbations, peak expiratory flow, exhaled nitric oxide examination, hospital anxiety and depression scale, asthma quality of life questionnaire, forced spirometry parameters (FVC, FEV1, and reversibility), and analytical parameters (eosinophilia and IgE).
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years with a diagnosis of asthma based on GEMA 5.2 2022. * Patients seen in the pulmonology service of the center. * Patients who have not previously received asthma education. * Capable of giving signed informed consent. Exclusion Criteria: * Patient who does not have a mobile device with Android or IOS system. * Lack of minimum technological knowledge for the use of the application (ESTOI). * People who are participating or have participated in a clinical trial in the last 6 months. * Patients diagnosed with other respiratory diseases except for obstructive sleep apnea (OSA), Asthma-COPD overlap syndrome (ACOS). * Patients with palliative or severe chronic illnesses that limit their life expectancy.
Contact & Investigator
Héctor Cabrerizo Carreño, M.N
PRINCIPAL INVESTIGATOR
Hospital Universitari de Bellvitge
Frequently Asked Questions
Who can join the NCT06116292 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06116292 currently recruiting?
Yes, NCT06116292 is actively recruiting participants. Contact the research team at hectorc95@gmail.com for enrollment information.
Where is the NCT06116292 trial being conducted?
This trial is being conducted at Barcelona, Spain.
Who is sponsoring the NCT06116292 clinical trial?
NCT06116292 is sponsored by Hospital Universitari de Bellvitge. The principal investigator is Héctor Cabrerizo Carreño, M.N at Hospital Universitari de Bellvitge. The trial plans to enroll 108 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.